Stable Coronary Disease Clinical Trial
Official title:
The Best Trial - Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen
To evaluate the safety and efficacy of the Janus OPTIMA Tacrolimus-Eluting Stent (Optima TES, CID) for the treatment of de novo coronary lesions when associated with short-term (two months) dual antiplatelet (aspirin + clopidogrel) regimen.
The present study is a post-market, prospective, international, two-center, single arm study
involving 60 patients with single, de novo non-complex coronary lesions.
Enrolled patients will be asked to return for follow-up clinical evaluation at 1, 6, 12 and
24 months. At 3 months there will be an additional follow-up by phone contact.
Furthermore, the first 15 patients should undergo angiographic and OCT follow-up at two
months. The remaining 45 patients should undergo angiographic and IVUS follow-up at 8 months.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05152888 -
The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk
|
Phase 4 | |
| Completed |
NCT02797158 -
Post TAVI Coronary REVASCularisation Guided by Myocardial Perfusion Imaging: a Prospective Open Label Pilot Study: The REVASC-TAVI Study
|
N/A | |
| Not yet recruiting |
NCT02214654 -
A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage
|
N/A |